Osteoblastic responses to LPS, glucose-oxidised LDL and minocycline: Therapeutic targets for periodontal and cardiometabolic diseases

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 1, 2012, Pages 73-84

  Tilakaratne, Aruni ^a   Soory, Mena ^b  

^a UNIVERSITY OF PERADENIYA   (Sri Lanka)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiometabolic diseases; Glucose; LDL; LPS; Minocycline; Oxidative stress; Periodontitis

Indexed keywords

ANDROSTENEDIONE; ANTIOXIDANT; BACTERIUM LIPOPOLYSACCHARIDE; GLUCOSE; GLUCOSE OXIDIZED LOW DENSITY LIPOPROTEIN; MINOCYCLINE; OXIDIZED LOW DENSITY LIPOPROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CULTURE; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME SUBSTRATE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIPID METABOLISM; METABOLIC DISORDER; OSTEOBLAST; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PERIODONTITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; WOUND HEALING;

ANDROSTENEDIONE; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CHROMATOGRAPHY, THIN LAYER; DIHYDROTESTOSTERONE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCOSE; HUMANS; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; METABOLIC DISEASES; MINOCYCLINE; OSTEOBLASTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PERIODONTAL DISEASES; TESTOSTERONE; TIME FACTORS; WOUND HEALING;

EID: 84856521396     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412799015281     Document Type: Article

References (86)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
2. Taiyeb-Ali TB, Raman RP, Vaithilingam RD. Relationship between periodontal disease and diabetes mellitus: An Asian perspective. Periodontol 2000 2011; 56: 258-68.
3. Alman AC, Johnson LR, Calverley DC, Grunwald G, Lezotte DC, Forster-Harwood J, et al. Loss of alveolar bone due to periodontal disease exhibits a threshold on the association with coronary heart disease. J Periodontol 2011; 82: 1304-13.
4. Soory, M. Relevance of dyslipidaemia and its consequences in periodontal patients with co-existing cardiovascular disease and diabetes mellitus: Therapeutic targets. Rec Patents Endocr Metab Immune Drug Discov 2009; 3: 214-24.
5. Fisher MA, Borgnakke WS, Taylor GW. Periodontal disease as a risk marker in coronary heart disease and chronic kidney disease. Curr Opin Nephrol Hypertens 2010;19: 519-26.
6. Yoshimura F, Murakami Y, Nishikawa K, Hasegawa Y, Kawaminami S. Surface components of Porphyromonas gingivalis. J Periodontal Res 2009; 44: 1-12.
7. Mustapha IZ, Debrey S, Oladubu M, Ugarte R. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: A systematic review and meta-analysis. J Periodontol 2007; 78: 2289-302.
8. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analysis on C-reactive protein in relation to periodontitis. J Clin Periodontol 2008; 35: 277-90.
9. Tuomainen AM, Hyvärinen K, Ehlers PI, Mervaala E, Leinonen M, Saikku P, et al. The effect of proatherogenic microbes on macrophage cholesterol homeostasis in apoE-deficient mice. Microb Pathog 2011; 51: 217-24.
10. Heur, M. Composition and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis. US7935367 (2011).
11. Soory M, El Shinnawi U. Diagnostic value of acute phase proteins in periodontal, psychosomatic and cardiometabolic diseases: Response to treatment. In: Veas F Eds. Acute phase proteins as early non-specific biomarkers of human and veterinary diseases. In Tech 2011; 43-68.
12. Acharya A, Bhavsar N, Jadav B, Parikh H. Cardioprotective effect of periodontal therapy in metabolic syndrome: A pilot study in Indian subjects. Metab Syndr Relat Disord 2010; 8: 335-41.
13. Solinger, A.M. Methods for the treatment of IL-1β- related diseases. US7695718 (2010).
14. Tseng W, Lu J, Bishop GA, Watson AD, Sage AP, Demer L, et al. Regulation of interleukin-6 expression in osteoblasts by oxidized phospholipids. J Lipid Res 2010; 51: 1010-6.
15. Hoogeveen RC, Ballantyne CM, Bang H, Heiss G, Duncan BB, Folsom AR, et al. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: The Atherosclerosis Risk in Communities Study. Diabetologia 2007; 50: 36-42.
16. Jenkins, P.J., Wu, M., Wu, D.S. Collection and diabetic use of Gibberellins. US7968596 (2011).
17. Jiang, X. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives. US7943778 (2011).
18. Meuwissen M, van der Wal AC, Niessen HW, Koch KT, de Winter RJ, van der Loos CM, et al. Co-localisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 2006; 59: 196-201.
19. Soory M. Chronic periodontitis as a risk factor for dyslipidaemic atherogenesis and diabetes: A bidirectional relationship. Proceedings of the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), Prague, Czech Republic, May 13-16, 2010.
20. Galli C, Passeri G, Macaluso GM. FoxOs, Wnts and oxidative stress-induced bone loss: New players in the periodontitis arena. J Periodont Res 2011; 46: 397-406.
21. Hamel P, Abed E, Brissette L, Moreau, R. Characterization of oxidized low-density lipoprotein-induced hormesis-like effects in osteoblastic cells. Am J Physiol Cell Physiol 2008; 294: C1021-33.
22. Leite LM, Carvalho AG, Ferreira PL, Pessoa IX, Gonçalves DO, Lopes AA, et al. Anti-inflammatory properties of doxycycline and minocycline in experimental models: An in vivo and in vitro comparative study. Inflammopharmacology 2011;19: 99-110.
23. Soory M. A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases. Open Dent J 2008; 2: 5-12.
24. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotecion. J Am Coll Cardiol 2008; 52: 1086-94.
25. Cook, R.O., Shrewsbury, SB., Ramadan, N.N. Pharmaceutical composition for the treatment of IL-8 mediated diseases. EP1958637 (2008).
26. Kawada, N., Mori, H., Yamada, H., Tanaka, M., Ochi, Y., Kayasuga, R. Bone densifying agent characterized by use of cathepsin k inhibitor with PTH. EP1741441 (2007).
27. Nikodemova M, Duncan ID, Watters JJ. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem 2006; 96: 314-23.
28. Lee SM, Yune TY, Kim SJ, Kim YC, Oh YJ, Markelonis GJ, et al. Minocycline inhibits apoptotic cell death via attenuation of TNFalpha expression following iNOS/NO induction by lipopolysaccharide in neuron / glia co-cultures. J Neurochem 2004; 91: 568-78.
29. Schildknecht S, Pape R, Muller N, Robotta M, Marquardt A, Burkle A, et al. Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 2011; 286: 4991-5002.
30. Payne JB, Golub LM, Stoner JA, Lee HM, Reinhardt RA, Sorsa T, et al. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: A randomized, double-masked, placebo-controlled clinical trial. J Am Dent Assoc 2011;142: 262-73.
31. Song X, Xu A, Pan W, Wallin B, Kivlin R, Lu S, et al. Minocycline protects melanocytes against H2O2-induced cell death via JNK and p38 MAPK pathways. Int J Mol Med 2008; 22: 9-16.
32. Eriksson, A., Lund, S.E. Metalloproteinase inhibitors. US7666892 (2011).
33. Ashley, RA., Hlavaka, J.J. 4-Dedimethylaminotracycline derivativs. US6946453 (2005).
34. Xu ZR, Hu L, Cheng LF, Qian Y, Yang YM. Dihydrotestosterone protects human vascular endothelial cells from H2O2 - induced apoptosis through inhibition of caspase-3, caspase-9 and p38 MAPK. Eur J Pharmacol 2010; 643: 254-9.
35. Ganesan K, Tiwari M, Balachandran C, Manohar BM, Puvanakrishnan R. Estrogen and testosterone attenuate extracellular matrix loss in collagen-induced arthritis in rats. Calcif Tissue Int 2008; 83: 354-64.
36. Pang ST, Dillner K, Wu X, Pousette A, Norstedt G, Flores-Morales A. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 2002; 43: 4897-906.
37. Demirbag R, Yilmaz R, Erel O. The association of total antioxidant capacity with sex hormones. Scand Cardiovasc J 2005; 39: 172-6.
38. Giretti MS, Simoncini T. Rapid regulatory actions of sex steroids on cell movement through the actin cytoskeleton. Steroids 2008; 73: 895-900.
39. Lee S.H, Heo JS, Lee MY, Han HJ. Effect of dihydrotestosterone on hydrogen peroxide-induced apoptosis of mouse embryonic stem cells. J Cell Phys 2008; 216: 269-75.
40. Imperlini E, Mancini A, Spaziani S, Martone D, Alfieri A, Gemei M, et al. Androgen receptor signalling induced by supraphysiological doses of dihydrotestosterone in human peripheral blood lymphocytes. Proteomics 2010; 10: 3165-75.
41. Hunt JV, Bottoms MA, Clare K, Skamarauskas JT, Mitchinson MJ. Glucose oxidation and low-density lipoprotein-induced macrophage ceroid accumulation: Possible implications for diabetic atherosclerosis. Biochem J 1994; 300: 243-49.
42. Figuero E, Soory M, Cerero R, Bascones A. Oxidant / antioxidant interactions of nicotine, Coenzyme Q10, Pycnogenol and phytoestrogens in oral periosteal finroblasts and MG63 osteoblasts. Steroids 2006; 71: 1062-72.
43. Soory M. Bacterial steroidogenesis by periodontal pathogens and the effect of bacterial enzymes on steroid conversions by human gingival fibroblasts in culture. J Periodont Res 1995; 30: 124-31.
44. Pershadsingh, H.A. Composition comprising novel PPAR ligands and anti-hyperlipaemic agents. US7867991 (2011).
45. Brown, L.A. Composition of flavonoids for use as cytoprotectants and methods of making and using them. US6528042 (2003).
46. Soory M. Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management? Rheumatol: Res Rev 2010; 2: 1-16.
47. Soory M. Chronic periodontitis as a risk marker for systemic diseases with reference to cardiometabolic disorders: Common pathways in their progression. Immunol Immunogen Insights 2010; 2: 7-21.
48. Bihain, B., Bougueleret, L., Yen-Potin, F. Lipoprotein-regulating medicaments. US7220722 (2007).
49. Ruvkun, G., Kaveh, A. Polynucleotide and polypeptide fat metabolism regulators and uses thereof. US7175999 (2007).
50. Soory M. Periodontal diseases and rheumatoid arthritis: A coincident model for therapeutic intervention. Curr Drug Metab 2007; 8: 750-7.
51. Kobayashi T, Murasawa A, Ito S, Yamamoto K, Komatsu Y, Abe A, et al. Cytokine gene polymorphisms associated with rheumatoid arthritis and periodontitis in Japanese adults. J Periodontol 2009; 80: 792-9.
52. Soory M, Donaldson N. Association of arthritis and other immunemediated disorders with periodontal disease amongst a cohort of periodontal patients. Controversies in Rheumatology and Autoimmunity. 1st International Congress, Florence, Italy, March 10-12, 2011. In: Clin Exp Rheumatol 2011; 29: 189 Abstract 162.
53. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: A pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539-48.
54. Aly HA, Lightfoot DA, El-Shemy HA. Bacterial lipopolysaccharide-induced oxidative stress in adult rat Sertoli cells in vitro. Toxicol in Vitro 2010; 24:1266-72.
55. Lakio L, Paju S, Alfthan G, Tiirola T, Asikainen S, Pussinen PJ. Actinobacillus actinomycetemcomitans serotype d-specific antigen contains the o antigen of lipopolysaccharide. Infect Immun 2003; 71: 5005-11.
56. Zhou Y, Carvey PM, Ling Z. Altered glutathione homeostasis in animals prenatally exposed to lipopolysaccharide. Neurochem Int 2007; 50: 671-80.
57. Allen JA, Diemer T, Janus P, Hales KH, Hales DB. Bacterial endotoxin lipopolysaccharide and reactive oxygen species inhibit Leydig cell steroidogenesis via perturbation of mitochondria. Endocrine 2004; 25: 265-75.
58. Almeida M, Han L, Ambrogini E, Bartell SM, Manolagas SC. Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: Counter regulation by estrogens or androgens. Mol Endocrinol 2010; 24: 2030-7.
59. Francia P, Cosentino F, Schiavoni M, Huang Y, Perna E, Camici GG, et al. p66 (Shc) protein, oxidative stress, and cardiovascular complications of diabetes: The missing link. J Mol Med 2009; 87: 885-91.
60. Nantermet P, Harada SI, Liu Y, Cheng S, Johnson C, Yu Y, et al. Gene expression analyses in Cynomolgus monkeys provides mechanistic insight into high density lipoprotein-cholesterol reduction by androgens in primates. Endocrinology 2008; 149: 1551-61.
61. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress -activated signalling pathways mediators of insulin resistance and beta cell dysfunction. Diabetes 2003; 52: 1-8.
62. Tamaki N, Tomofuji T, Ekuni D, Yamanaka R, Morita M. Periodontal treatment decreases plasma oxidized LDL level and oxidative stress. Clin Oral Investig 2010; [Epub ahead of print].
63. Lakio L, Lehto M, Tuomainen AM, Jauhiainen M, Malle E, Asikainen S, et al. Proatherogenic properties of lipopolysaccharide from the periodontal pathogen Actinobacillus actinomycetemcomitans. J Endotoxin Res 2006; 12: 57-64.
64. Taguchi K, Tamba M, Bannai S, Sato H. Induction of cystine/glutamate transporter in bacterial lipopolysaccharide induced endotoxaemia in mice. J Inflamm 2007; 4: 20-6.
65. Reddy MM, Mahipal SV, Subhashini J, Reddy MC, Roy KR, Reddy GV, et al. Bacterial lipopolysaccharide-induced oxidative stress in the impairment of steroidogenesis and spermatogenesis in rats. Reprod Toxicol 2006; 22: 493-500.
66. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, et al. Human high-density lipoprotein of the JNK pathway induced by human oxidized low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007; 50: 1304-14.
67. Pabreja K, Dua K, Sharma S, Padi SS, Kulkarni SK. Minocycline attenuates the development of diabetic neuropathic pain: Possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol 2011; 661:15-21.
68. Soory M. Redox status in periodontal and systemic inflammatory conditions including associated neoplasias: Antioxidants as adjunctive therapy? Infect Disord Drug Targets 2009; 9: 415-27.
69. Galli C, Passeri G, Macaluso GM. FoxOs, Wnts and oxidative stress-induced bone loss: New players in the periodontitis arena? J Periodontal Res 2011; 46: 397-406.
70. Kousteni S. FoxOs: Unifying links between oxidative stress and skeletal homeostasis. Curr Osteoporos Rep 2011; 9: 60-6.
71. Manolagas SC, Almeida M. Gone with the Wnts: Beta-catenin, Tcell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007; 21: 2605-14.
72. Masat, L., Haak-Frendscho, M., Horwitz, A.H., Chen, G., Roell, M. Method of treating an IL-1 related autoimmune disease or condition. US7829093 (2010).
73. Engerbretson, S.P. Methods for facilitating metabolic control. US7732478 (2010).
74. Bullon P, Morillo JM, Ramirez-Tortosa MC, Quiles JL, Newman HN, Battino M. Metabolic syndrome and periodontitis: Is oxidative stress a common link? J Dent Res 2009; 88: 503-18.
75. Gümüş P, Buduneli N, Cetinkalp S, Hawkins SI, Renaud D, Kinane DF, et al. Salivary antioxidants in patients with type 1 or 2 diabetes and inflammatory periodontal disease: A case-control study. J Periodontol 2009; 80:1440-6.
76. Allen EM, Matthews JB, O'Connor R, O'Halloran D, Chapple IL. Periodontitis and type 2 diabetes: Is oxidative stress the mechanistic link? Scott Med J 2009; 54:41-7.
77. Ohnishi T, Bandow K, Kakimoto K, Machigashira M, Matsuyama T, Matsuguchi T. Oxidative stress causes alveolar bone loss in metabolic syndrome model mice with type 2 diabetes. J Periodontal Res 2009; 44: 43-51.
78. Griswold-Prenner, I. Methods of inhibiting amyloid toxicity. US7901683 (2011).
79. Hamada Y, Fujii H, Fukagawa M. Role of oxidative stress in diabetic bone disorder. Bone 2009; 45 (Suppl 1): S35-8.
80. Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007; 43:294-315.
81. Paquette DW, Ryan ME, Wilder RS. Locally delivered antimicrobials: Clinical evidence and relevance. J Dent Hyg 2008; 82 (Suppl 3):10-15.
82. Renvert S, Lessem J, Dahlén G, Renvert H, Lindahl C. Mechanical and repeated antimicrobial therapy using a local drug delivery system in the treatment of peri-implantitis: A randomized clinical trial. J Periodontol 2008; 79: 836-44.
83. Cazalis J, Tanabe S, Gagnon G, Sorsa T, Grenier D. Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation 2009; 32:130-7.
84. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action. Pharmacol Res 2011; 63: 102-7.
85. Leite LM, Carvalho AG, Ferreira PL, Pessoa IX, Gonçalves DO, Lopes AA, et al. Anti-inflammatory properties of doxycycline and minocycline in experimental models: An in vivo and in vitro comparative study. Inflammopharmacology 2011;19: 99-110.
86. Monk E, Shalita A, Siegel DM. Clinical applications of nonantimicrobial tetracyclines in dermatology. Pharmacol Res 2011; 63:130-45.